Directly engineered to interface with Korean Cosmetic Act requirements, K-FDA safety protocols, and advanced bio-pharma discovery programs across Gangnam, Pangyo, and Osong.
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers
Seoul stands as the apex driver for the global K-Beauty boom and next-generation phyto-pharmaceutical developments. Understanding local industry bottlenecks and high standard requirements is paramount for international research and supply partnerships.
The Seoul metropolitan sphere concentrates over 68% of South Korea's high-tier biopharmaceutical startups in clusters like Pangyo Techno Valley and Magok Industrial Complex. These enterprises heavily demand pre-validated cellular target assays, anti-inflammatory mechanisms, and high-throughput botanical fraction profiling to feed aggressive R&D pipelines.
Governed strictly under the Korean Ministry of Food and Drug Safety (MFDS), cosmetics claiming whitening, anti-wrinkle, or skin barrier restoration require exacting active constituent quantification. Seoul cosmetic houses require rapid separation, identification, and toxicity verification for novel herbal fractions to substantiate clean-label marketing claims.
While Seoul's research teams excel in genetic and clinical biology, domestic pilot-scale extraction infrastructure and bulk phytochemical isolation facilities are cost-prohibitive. High land values and stringent environmental regulations make cross-border CDMO collaborations indispensable for scalable manufacturing.
The shift toward precision phyto-pharmacology demands modern screening methods that supersede classical trial-and-error extraction. Global procurement requires deep analytical characterization, zero batch variation, and validated therapeutic windows.
Global pharmaceutical paradigms no longer isolate single molecules blindly. High-throughput mass spectrometry, combined with target-affinity screening, identifies how synergistic botanical complexes bind to multiple disease pathways simultaneously. This is essential for modern metabolic, neuroprotective, and immune applications where single-target drugs frequently exhibit toxicity or tolerance.
Stricter limits established by USP, EP, and K-FDA regarding residual agrochemicals, heavy metals, polycyclic aromatic hydrocarbons (PAHs), and organic solvent residues require upfront active screening to filter out raw botanical matrices prone to contamination, protecting formulation brands against costly recalls.
Partnering with MedGence (Yineng Pharma) provides global brands with a strategic synergy: combining top-tier screening protocols with unmatched production scalability, extensive botanical access, and radical cost-efficiency.
Situated in Hunan, China, MedGence leverages rapid access to primary cultivation regions spanning thousands of herbal species. We screen, isolate, and scale active principles directly at origin, eliminating secondary transport degradation and exorbitant broker margins.
Transition seamlessly from analytical milligram-level fractions in our screening labs to multi-ton commercial extract batches. Our pilot facilities and commercial factories operate under strict ISO, cGMP, and non-disclosure standards to safeguard customer formulation IP.
Our dedicated team of 300+ scientists executes concurrent workflows: analytical method development (HPLC, HPTLC, GC), in vitro testing, animal toxicity profiling, and process optimization occur synchronously, reducing typical development cycles by over 40%.
How cross-border biopharma brands, nutraceutical ventures, and personal-care leaders leverage screening data to achieve undeniable market validation.
Local skincare laboratories require isolated ginsenosides, madecassoside derivatives, and novel polyphenols screened against tyrosinase inhibition and elastase suppression assays. Formulators demand clear chromatographic fingerprints to meet K-MFDS standards without batch color shifts or crystallization issues.
Global wellness brands look to Seoul as an innovation testbed for anti-glycation, hepatic protection, and mitochondrial support products. Screening identifies specific flavonoids and polysaccharides that can be encapsulated into softgels, oral liquids, and effervescent granules without degradation.
Emerging ventures require comprehensive data files including in vitro receptor affinity assays, acute LD50 safety profiles, and dose-dependent animal pharmacokinetic (PK) studies to pass preliminary regulatory scrutiny and attract private equity capitalization in Korea and North America.
Clear, technical clarifications regarding screening methodologies, intellectual property preservation, regulatory alignment, and contract manufacturing.
We execute multi-stage screening beginning with phytochemical profile matching across our extensive proprietary database. Candidate plants undergo targeted solvent fractionation, accompanied by cell-based bioassays (e.g., anti-inflammatory, antioxidant, glucose metabolism, antimicrobial) to pinpoint active fractions. We then isolate key markers using preparative chromatography for structure elucidation via MS and NMR.
All analytical test methods, including HPTLC identification and HPLC quantitative determination, are developed in accordance with international pharmacopeial validation standards (ICH Q2 guidelines), which are recognized by the Korean MFDS. We provide complete validation reports including precision, accuracy, limit of detection (LOD), and limit of quantitation (LOQ).
All contract research and manufacturing engagements are secured under strict Non-Disclosure Agreements (NDAs). MedGence operates on an entrusted service model: proprietary fractions, chromatographic conditions, process parameters, and customer-supplied formulations remain exclusively the property of the client.
Yes. Unlike academic research institutes, we operate dedicated pilot plants and commercial facilities. Once the active molecule or enriched fraction is identified and validated in vitro or in vivo, our chemical engineering team establishes industrial-scale extraction, membrane separation, and spray drying protocols.
Active ingredients can be provided as standardized spray-dried powders, concentrated viscous liquids, high-purity crystalline pastes, or supercritical volatile oils. For end-dosage formulations, we manufacture OEM/CDMO oral liquids, hard-shell capsules, softgels, tablets, and granules ready for retail boxing.
Phytochemical content varies widely based on terroir, microclimate, and growth maturity. Our seasonal and geographic potency evaluation studies analyze marker constituent levels across origins, ensuring brands secure herbal raw materials with peak bioactivity at optimal procurement pricing.
Integrate your discovery initiatives with our end-to-end analytical, preclinical, clinical, and manufacturing service line.
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
China Establishment of analysis methods of active ingredient(s) Supplier, Suppliers
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
OEM In Vitro Test /Research Service Manufacturers, Suppliers
China Screening of the active ingredient(s) of plants Manufacturer, Manufacturers
Connect directly with our senior research team to formulate custom screening cascades, validate analytical methodologies, or schedule pilot-scale batch production under strict non-disclosure conditions.
Send Inquiry Now